A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies. (2023)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1158/2643-3230.bcd-22-0205
PubMed Identifier: 37102976
Publication URI: http://europepmc.org/abstract/MED/37102976
Type: Journal Article/Review
Volume: 4
Parent Publication: Blood cancer discovery
Issue: 4
ISSN: 2643-3230